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Review Article
intROductiOn
Trauma increases the possibility of venous thromboembolism 
(VTE), leading to higher mortality in the hospitalized 
population.[1-3] Traumatic brain injury (TBI) is considered a 
global public health issue; About 75%–80% are minor injuries 
and more frequent among adolescents and young adults.[4,5] 
The Centers for Disease Control and Prevention estimated 
1.7 million persons as annual victims TBI, 275,000 are 
hospitalized, and 52,000 die inclusive of different postinjury 
complications.[6] This manuscript presents a narrative review 
of the VTE reported in the published literature of patients 
with TBI.
Abstract
In this systematic review, we detailed the current understanding and controversies on venous thromboembolism as the sequel following 
traumatic brain injury (TBI). The review was conducted on the literature survey to find the thromboembolic morbidities in TBI patients. This 
review presented the thromboembolic sequel of patients with TBI by a comprehensive focused assembly of research publications by searching 
various resources. A search strategy with specific inclusion criteria was performed in PubMed, Cochrane, Web of Science, and the WHO Global 
Health Library. TBI is related with the incremental presence of spectrum of thromboembolic disorders from primary and secondary injuries 
by the significant increases in the concentrations of the initiating factors of the coagulation cascade. The incidences of thromboembolism vary 
on factors like the severity of TBI, methods of prophylaxis used or the processes to diagnose embolic involvement. The most effective time 
for the initiation of antithrombotic therapy chemoprophylaxis should be initiated after 24 h or after 72 h in patients with brain trauma is still 
a controversial issue. Patients with brain injury are at increased risk for thromboembolism for which prophylaxis and timely management are 
highly recommended, and this should be available in all levels of care.
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MethOds
We explored a comprehensive, focused collection of research 
publications by searching various resources; University 
publications, hospital-based studies, retrospective data mining, 
surveys, presentations, meeting, and personal communications 
about recent surveys not included in previous analyses 
in which long-term thromboembolic sequel of traumatic 
brain injuries were reported. A search strategy with specific 
inclusion criteria was performed in PubMed, Cochrane, Web 
of Science, and the WHO Global Health Library. The literature 
search for “TBI” and downstream “VTE” in PubMed with 
specific subject headings related to “TBI” (medical subject 
heading [MeSH] Terms) OR AND “VTE” (complete fields), 
OR AND “injury” (complete fields), “head injury” (complete 
fields) AND “thromboembolism” (MeSH Terms) was used 
as the search terms for each database. All the crucial items 
were identified for inclusion in this review that reported on 
“TBI” and “VTE” from 1966 to 2017. Any other published 
reports relating “TBI” and “VTE” in South-east Asia including 
India, were also explored. The research works were further 
classified into clinical and epidemiological studies for better 
internalization. The main outcome variables were specific 
patterns of TBI and associated thromboembolism from 
published reports.
epideMiOlOgy
Worldwide, the new cases of VTE are 1–2/1000 patients/year[1] 
and the incidence of deep-vein thrombosis (DVT) after trauma 
is approximately between 6% and 58%.[2] The United States 
researchers reported nearly 300,000 deaths/year from VTE.[3] 
VTE occurs in approximately 25% of persons with isolated 
brain lesions and up to 50% of polytraumatized individuals 
with brain injuries.[7] The TBI is an independent risk factor to 
develop thromboembolic complications,[8] due to prolonged 
immobilization, systemic hypercoagulability,[3,9,10] and delay in 
the onset of prophylaxis.[7] Out of the hospitalized patients with 
TBI, 54% are at risk of VTE.[11] Despite this incidence of VTE 
in neurosurgical patients varies between 19% and 54% taking 
into account the prophylactic measures, timely diagnosis, and 
prolonged stay (preoperative and postoperative).[12]
pAthOphysiOlOgy
TBI is classified as primary and secondary lesions. The 
primary lesions occur due to an external mechanical impact 
on the head[4] that causes damage to blood vessels and brain 
tissue,[13] and their severity depends on the force exerted on 
the brain. Subsequently, an alteration of the blood–brain 
barrier, hemodynamic instability, and activation of the 
immune system are observed, triggering greater neurological 
damage that corresponds to a secondary cerebral injury.[14] The 
secondary lesions also include excesses of the free radicals, 
excessive release of neurotransmitters, and mitochondrial 
dysfunction among other organic alterations that seek to 
compensate for the instability caused by the impact.[13] 
Excessive synthesis and neurochemical releases alter blood 
flow, ion homeostasis, and downstream metabolic effects.[4] 
Secondary injuries may occur due to emboli production or 
hemorrhagic progression, probably due to mechanisms such 
as tissue factor release, hypoperfusion, platelet dysfunction, 
and disseminated intravascular coagulation.[15] The disruptions 
of the neuronal and axonal cell membranes lead to the release 
of neurotransmitters and ionic changes.[16,17]
incidence And Risk FActORs between tRAuMAtic 
bRAin injuRy And venOus thROMbOeMbOlisM
Venous thromboembolic complications occur more frequently 
in patients with trauma and may cause an increase in the 
mortality rate.[1,4] Approximately 25% of people suffering from 
isolated brain injuries and 50% of polytraumatized patients 
with brain injuries can present with VTE.[7] Specifically, 
in the cases of injures patients, of DVT reported among 
20%–25% of the new cases.[4] However, the incidence of VTE 
can be very variable because factors such as the severity of 
the trauma, methods of prophylaxis used or the processes to 
diagnose embolic involvement must be taken into account.[2,4] 
There are several risk factors and risk correlates to develop 
VTE viz. Obesity, hypercoagulable states, smoking, having 
previously presented a VTE, among others.[4,18] However, 
most cases of VTE have been related to spinal cord injuries 
with paralysis, head injuries, and fractures of the hip, 
pelvis, or lower limb, with TBI being the criterion that most 
frequently causes VTE. This may be due to three aspects: (a) 
the extensive state of immobility presented by patients with 
TBI, a consequence of their poor state of consciousness; (b) 
the late start of prophylactic treatment of VTE, seeking to 
avoid the consequences such as the expansion of intracranial 
haemorrhage (ICH); and (c) hypercoagulability thanks to the 
activation of tissue factor, platelets, and other procoagulant 
agents such as the Von Willebrand factor.[2,7,12]
RelAtiOnship between tRAuMAtic bRAin injuRy And 
venOus thROMbOeMbOlisM
For the evolution of VTE, in the majority of the injury 
cases, the appearance of the Virchow Triad (vascular 
injury, venostasis, and hypercoagulability) is the main 
cause. This triad, accompanied by other risk factors, such 
as immobility, promotes this condition.[1,4] Immobilization 
of patients causes an absence of pulsatile blood flow, 
generating an accumulation of venous blood promoting local 
hypoxia, which activates the coagulation cascade.[19] After 
the TBIs, endothelial functionality is affected, promoting 
the prothrombotic environment that increases the risk of 
thrombosis. Subsequently, there is a hypercoagulability due 
to excessive coagulation, increased fibrinolytic inhibition, and 
decreased inhibition of coagulation.[4] On the other hand, in 
the TBI, there is a significant increase in the concentrations of 
the initiating factor of the coagulation process, tissue factor, or 
thromboplastin. This could partially explain the high incidence 
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of systemic thromboembolic problems in this type of patients 
due to the procoagulant state generated by their organism.[4,18]
MAnAgeMent
The thrombo-prophylactic interventions are organized 
into pharmacotherapy with anticoagulants, mechanical 
prophylaxis, and use of inferior vena cava (IVC) filters.[18] 
The use of subcutaneous heparin as a prophylactic measure 
has shown that it decreases the risk of DVT without generating 
complications in neurosurgical patients when administered 
between 24 and 48 h after surgery.[8] In addition, research 
groups reported the superiority of low-molecular-weight and 
low doses of unfractionated heparin (UFH) decreases VTE 
without the higher probability of bleeds in neurosurgical cases. 
Judicious use of intermittent pneumatic compression devices 
and graduated compression stockings has shown promising 
results in reducing VTE, though these failed to show greater 
effectiveness and better prophylaxis.[12]
pROphylActic Agents FOR venOus 
thROMbOeMbOlisM AFteR Acute ceRebRAl injuRy
Among the main primary prophylactic options are mechanical 
and pharmacological options.[4,18] The mechanical modalities 
and pharmacological prophylaxis have been related with an 
elevated risk of bleeding.[18]
MechAnicAl Anti‑thROMbOtic pROphylAxis
This type of prophylactic modality has as the main purpose to 
avoid stasis and ignite the fibrinolytic pathway, thus reducing 
the incidence of DVT.[3] These can act as monotherapy, in 
cases where there is a contraindication for the pharmacological 
option, or contributing in a complementary way to it.[15,18] 
The main advantage of the use of mechanical prophylaxis is 
the lack of action on coagulation, greatly reducing the risk 
of hemorrhage.[18] However, there are several disadvantages 
such as costefficiency, which alone may be insufficient 
to counteract the death and illness associated with DVT, 
despite the economic costs that this prophylactic treatment 
can cause.[15,18]
chAllenges
Usually, DVT is not clinically evident. The absence of signs 
and symptoms, higher incidence, mortality of DVT, and the 
cost of management increase the importance for the realization 
of prophylaxis for DVT and pulmonary embolism.[3] Most 
neurosurgeons are scared for anticoagulant use for the 
management of VTE in TBI cases to circumvent ICH, yet 
keeping in mind about the risk of ICH, chemoprophylaxis is 
used to avoid VTE.[8,9,15,20] In 45% of patients with TBI ICH 
is present, this means that medical personnel must balance 
the risk of hemorrhage progression and DVT before starting 
pharmacological prophylaxis.[9]
Anti‑thROMbOtic cheMO‑pROphylAxis
The question about the use of anticoagulation prophylaxis drugs 
in TBI has been debated for decades. Some neurosurgeons 
approach the concept with hesitation based on the precept 
that anticoagulation will increase the risk of cerebral 
hemorrhage or expand an already established one.[15,21] The 
management guidelines for patients with TBI address positive 
role of chemotherapy for optimal prophylaxis with specific 
precautions. However, multiple studies promote the use of 
this prophylactic method in humans with TBI.[15] Another 
proposed mechanism for antithrombotic prophylaxis in patients 
with TBI, apart from mechanical mechanisms, is the use of 
medications, this process being known as chemoprophylaxis. 
Among the proposed medications are UFHs; these drugs have 
been evaluated in various studies.[3,22] Heit et al., in their study, 
on survival predictors, after a thromboembolism, the effect 
of the use of 5000 units of heparin every 8 h was evaluated 
subcutaneously in patients with high thromboembolic risk, with 
guidelines of 2 h before surgery and 7 days postoperatively; 
in which they found a three-fold decrease in DVT incidence.
[23] For Geerts et al., in their study, low doses of UFH are 
not effective when performed in trauma patients, and their 
effectiveness is reduced in patients with high-risk trauma.[24] 
Consequently, low doses of UFH should not be used unless 
it is of low-molecular-weight heparin (LMWH), namely 
enoxaparin 30 mg 12 hourly, decreasing risk of DVT by 58%. 
As a result, LMWH used initially when primary hemostasis 
was promoted as the predilection technique promoted for 
DVT in major trauma.[25] With regard to low-molecular-weight 
heparins, the literature raises many issues on their clinical 
use.   Among these, enoxaparina, dalteparina, enoxaparin 
have the advantage as their dosage are based on units of 
measurement viz. Milligrams or milligrams per kilogram 
body weight, compared to the other heparins whose dosages 
are based on international units or international units per kilo 
per kilogram body weight.[26]
Currently, studies are underway with another drug whose 
mechanism of action is to act as an anti-factor X inhibitor, 
whose indication is based on DVT prophylaxis 2.5 mg daily in 
postoperative hip and knee replacement; even though Lu et al., 
in their study, of DVT prevention in cases with trauma and 
higher thromboembolism risk, concluded that fondaparinux 
was effective for DVT, in trauma patients, yet it has no 
indication at present for this type of patients.[27]
MOnitORing OF Anti‑xA FActOR in tRAuMAtized 
pAtients with high Risk OF thROMbOeMbOlisM
Currently, multiple investigations have suggested that the 
standard dosage of LMWH, in patients with brain injury or 
any type of trauma (30 mg subcutaneous 12 hourly), may not 
be able to impart prophylaxis, in high-risk trauma cases.[3,28,29] 
In the patients described above, the doses of LMWHs should 
be adjusted taking into account the level of anti-factor Xa. 
Because <0.1 is the value that is considered normal for the 
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anti-factor Xa, its measurement is indicated before the number 
4 dose of these heparins; in the case that the anti-factor Xa is 
normal (<0.1), it is considered that enoxaparin should be adjusted 
to a dose of 40 mg subcutaneous 12 hourly; it is necessary to take 
as a point of reference that a patient with an anti-factor value 
Xa >0.5 is considered therapeutically anticoagulant and the 
objectives will be to maintain the anti-factor Xa values between 
0.2 and 0.5.[30] In case the sub-therapeutic value continues, it is 
considered to adjust the dose to 50 mg every 12 h of enoxaparin. 
This approach promotes effective prophylaxis and decreases 
subtherapeutic therapies that would raise the probability of 
thromboembolism in injury victims.[31]
tiMe FOR the cheMO‑pROphylAxis OF deep venOus 
thROMbOsis in Acute ceRebRAl injuRy
Current literature based on determining the most effective time 
for the initiation of antithrombotic therapy, has investigated 
whether this chemoprophylaxis should be initiated after 24 h 
or after 72 h in TBI. LMWH (enoxaparin, 30 mg 12 hourly.) or 
UFH (5000 IU 12 hourly) was used in severe TBI.[16,17,20] It was 
evidenced that the rate of ICH does not increase if it is applied 
before 72 h; On the contrary, the efficacy of chemoprophylaxis 
decreased from 3.6% to 15.4%.[25,32,33]
Risk OF pOstcheMOpROphylAxis ceRebRAl 
heMORRhAge
One of the problems associated with antithrombotic 
chemoprophylaxis in brain trauma is the appearance of de novo 
cerebral hemorrhage or the exacerbation of an already established 
TBI. Taking into account retrospective studies of progression 
of cerebral hemorrhages in patients who were followed up 
with computed tomography (CT) scans, it was demonstrated 
that antithrombotic chemoprophylaxis can increase the rate 
of cerebral hemorrhages.[33,34] It was established that bleeding 
rates increased in susceptible patients with higher criteria of 
pre-established risk factors.[19,33] That is why you should identify 
posttraumatic patients with an increased risk of these conditions. 
Literature reports that several criteria are proposed to classify 
these patients, namely, Parkland protocol or Berne-Norwood 
criteria, categorizing them into high-, moderate-, and low-risk 
for cerebral hemorrhage. The modification of the Parkland 
protocol, which was first, proposed by Berne and Norwood and 
thus is now called the Berne-Norwood criteria or new Parkland 
protocol advised to initiate LMWH within 24 h for low-risk 
TBI, within 72 h for moderate risk TBI and consider placing an 
IVC filter in case of high-risk TBI. Phelan et al. in their study of 
stratification of the risk of bleeding in brain trauma, showed that 
antithrombotic chemoprophylaxis after 24 h did not cause an 
increase in cerebral hemorrhage rates.[33,35] Further, in an internal 
validation study, Pastorek et al.[36] modified the moderate and 
high-risk category recommendations to either LMWH initiation 
at 72 h if the CT scan is table at that time or to delay the same 
until the hemorrhage pattern stabilizes.
cOnclusiOns
VTE is a common sequel in medical and surgical emergencies. 
Trauma cases usually face the Virchow’s Triad comprising 
stasis, injury, and thrombophilia, following TBI. The rationale 
toward prophylactic interventions are targeted on the spectrum, 
the diagnostic dilemma, the fatality as well as disability as 
well and last but not the least, cost reduction for the holistic 
approach of thromboembolism intervention.
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